+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cell Therapy Human Raw Materials Market Size, Share & Trends Analysis Report, Product (Cell Culture Media, Cell Culture Sera, Cell Culture Supplements), End Use, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 120 Pages
  • January 2024
  • Region: Global
  • Grand View Research
  • ID: 5936567
Description Jump to:
The global cell therapy human raw materials market is expected to reach USD 11.44 billion by 2030 and is projected to expand at a CAGR of 22.32% from 2024 to 2030. This is attributed to increasing investment in cell therapy research & development, growing number of clinical trials and rising adoption of regenerative & personalized medicines.

The field of cell therapy R&D has seen substantial growth in investments in recent years, fueling the development of next-generation treatments like CAR T-cell therapies. This surge in activity has advanced the understanding of cell biology, immunology, & gene editing, leading to the identification of novel therapeutic targets and the optimization of cell manufacturing processes. The improved understanding of the tumor microenvironment and immune system evasion mechanisms has enabled researchers to design CAR-T cells that effectively target and eliminate cancer cells. These advancements are being driven by increased funding in cancer immunotherapy research and are expected to propel the cell therapy raw materials market. For instance, in August 2023, Cellares, a startup specializing in cell therapy production, secured an additional USD 255 million in funding as investors continued to invest heavily in the company. Bristol Myers Squibb is among the supporters of Cellares, which asserts that its manufacturing
apabilities can outperform traditional Contract Development and Manufacturing Organization (CDMO) facilities.

Furthermore, the expanding landscape of clinical trials in the field of cell therapy has become a driving force influencing the cell therapy human raw materials market. As the number of clinical trials investigating the efficacy and safety of cell-based therapies continues to rise, the demand for specific raw materials essential to these trials is experiencing a considerable upswing.

However, ethical concerns in stem cell research restrain the cell therapy human raw materials market, shaping the landscape with unique challenges. One prominent ethical dilemma revolves around the use of human-derived materials, particularly stem cells, which raises issues regarding the source, consent, and potential exploitation. Obtaining these materials may involve ethical considerations related to embryonic stem cells, as their extraction typically involves the destruction of embryos, sparking debates on the moral status of the early human life involved.

Cell Therapy Human Raw Materials Market Report Highlights

  • The cell culture supplements segment dominated the product segment with a revenue share of 27.84% in 2023, owing to the rising demand for animal-free cell-based therapies
  • The cell culture media segment is expected to grow at the fastest CAGR over the forecast period due to the advancements in cell culture media technology which focuses on development of specialized formulations
  • Based on end use, the biopharmaceutical & pharmaceutical companies segment dominated the market in 2023. On the other hand, the CROs & CMOs segment is expected to witness the fastest growth over the forecast period
  • North America region dominated the market owing to factors such as the presence of key market players like Thermo Fisher Scientific, Inc, Actylis, ACROBiosystems and the growth in pharmaceutical & biotechnology research sectors in this region
  • Asia-Pacific is expected to register the fastest growth over the forecast period due to several companies expanding their presence in regions like Japan

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Product
1.1.2. End Use
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objective
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis:
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. MARKET DRIVER ANALYSIS
3.2.1.1. Increasing investments in cell therapy research and development
3.2.1.2. Growing number of clinical trials
3.2.1.3. Rising adoption of regenerative medicine
3.2.2. MARKET RESTRAINT ANALYSIS
3.2.2.1. Ethical concerns related to stem cell research
3.2.2.2. High cost associated with the production and procurement of raw materials
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Cell Therapy Human Raw Materials Market: Product Movement Analysis
4.2. Cell Culture Media
4.2.1. Cell culture media market estimates and forecasts, 2018-2030 (USD Million)
4.3. Cell Culture Sera
4.3.1. Cell culture sera market estimates and forecasts, 2018-2030 (USD Million)
4.4. Cell Culture Supplements
4.4.1. Cell culture supplements market estimates and forecasts, 2018-2030 (USD Million)
4.4.2. Proteins
4.4.2.1. Proteins market estimates and forecasts, 2018-2030 (USD Million)
4.4.3. Growth Factors
4.4.3.1. Growth factors market estimates and forecasts, 2018-2030 (USD Million)
4.4.4. Nucleotides
4.4.4.1. Nucleotides market estimates and forecasts, 2018-2030 (USD Million)
4.4.5. Other Supplements
4.4.5.1. Other supplements market estimates and forecasts, 2018-2030 (USD Million)
4.5. Reagents & Buffers
4.5.1. Reagents & buffers market estimates and forecasts, 2018-2030 (USD Million)
4.6. Other Raw Materials
4.6.1. Other raw materials market estimates and forecasts, 2018-2030 (USD Million)
Chapter 5. End Use Group Business Analysis
5.1. Cell Therapy Human Raw Materials Market: End Use Movement Analysis
5.2. Biopharmaceutical & Pharmaceutical Companies
5.2.1. Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2018-2030 (USD Million)
5.3. CROs & CMOs
5.3.1. CROS & CMOs market estimates and forecasts, 2018-2030 (USD Million)
5.4. Academic & Research Institutions
5.4.1. Academic & research institutions market estimates and forecasts, 2018-2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Cell Therapy Human Raw Materials Share By Region, 2023 & 2030
6.2. North America
6.2.1. North America Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Competitive Scenario
6.2.2.3. Regulatory Framework
6.2.2.4. Target Disease Prevalence
6.2.2.5. U.S. Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Competitive Scenario
6.2.3.3. Regulatory Framework
6.2.3.4. Target Disease Prevalence
6.2.3.5. Canada Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.3. Europe
6.3.1. Europe Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.3.2. UK
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Regulatory Framework
6.3.2.4. Target Disease Prevalence
6.3.2.5. UK Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. Regulatory Framework
6.3.3.4. Target Disease Prevalence
6.3.3.5. Germany Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Competitive Scenario
6.3.4.3. Regulatory Framework
6.3.4.4. Target Disease Prevalence
6.3.4.5. France Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Competitive Scenario
6.3.5.3. Regulatory Framework
6.3.5.4. Target Disease Prevalence
6.3.5.5. Italy Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Competitive Scenario
6.3.6.3. Regulatory Framework
6.3.6.4. Target Disease Prevalence
6.3.6.5. Spain Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Competitive Scenario
6.3.7.3. Regulatory Framework
6.3.7.4. Target Disease Prevalence
6.3.7.5. Denmark Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Competitive Scenario
6.3.8.3. Regulatory Framework
6.3.8.4. Target Disease Prevalence
6.3.8.5. Sweden Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Competitive Scenario
6.3.9.3. Regulatory Framework
6.3.9.4. Target Disease Prevalence
6.3.9.5. Norway Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.4. Asia-Pacific
6.4.1. Asia-Pacific Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. Target Disease Prevalence
6.4.2.5. Japan Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Target Disease Prevalence
6.4.3.5. China Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. Target Disease Prevalence
6.4.4.5. India Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.4.5. Australia
6.4.5.1. Key Country Dynamics
6.4.5.2. Competitive Scenario
6.4.5.3. Regulatory Framework
6.4.5.4. Target Disease Prevalence
6.4.5.5. Australia Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.4.6. Thailand
6.4.6.1. Key Country Dynamics
6.4.6.2. Competitive Scenario
6.4.6.3. Regulatory Framework
6.4.6.4. Target Disease Prevalence
6.4.6.5. Thailand Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.4.7. South Korea
6.4.7.1. Key Country Dynamics
6.4.7.2. Competitive Scenario
6.4.7.3. Regulatory Framework
6.4.7.4. Target Disease Prevalence
6.4.7.5. South Korea Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Target Disease Prevalence
6.5.2.5. Brazil Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.5.3. Mexico
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. Target Disease Prevalence
6.5.3.5. Mexico Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.5.4. Argentina
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. Target Disease Prevalence
6.5.4.5. Argentina Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.6. MEA
6.6.1. MEA Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Target Disease Prevalence
6.6.2.5. South Africa Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Target Disease Prevalence
6.6.3.5. Saudi Arabia Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. Target Disease Prevalence
6.6.4.5. UAE Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework
6.6.5.4. Target Disease Prevalence
6.6.5.5. Kuwait Cell Therapy Human Raw Materials, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2023
7.4. Company Profiles/Listing
7.4.1. Thermo Fisher Scientific, Inc
7.4.1.1. Overview
7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Merck KGaA
7.4.2.1. Overview
7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Actylis
7.4.3.1. Overview
7.4.3.2. Product Benchmarking
7.4.3.3. Strategic Initiatives
7.4.4. ACROBiosystems
7.4.4.1. Overview
7.4.4.2. Product Benchmarking
7.4.4.3. Strategic Initiatives
7.4.5. STEMCELL Technologies
7.4.5.1. Overview
7.4.5.2. Product Benchmarking
7.4.5.3. Strategic Initiatives
7.4.6. Grifols, S.A.
7.4.6.1. Overview
7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Charles River Laboratories
7.4.7.1. Overview
7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. RoosterBio, Inc.
7.4.8.1. Overview
7.4.8.2. Product Benchmarking
7.4.8.3. Strategic Initiatives
7.4.9. PromoCell GmbH
7.4.9.1. Overview
7.4.9.2. Product Benchmarking
7.4.9.3. Strategic Initiatives
7.4.10. Danaher
7.4.10.1. Overview
7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. BioIVT
7.4.11.1. Overview
7.4.11.2. Product Benchmarking
7.4.11.3. Strategic Initiatives
7.4.12. GeminiBio
7.4.12.1. Overview
7.4.12.2. Product Benchmarking
7.4.12.3. Strategic Initiatives
7.4.13. Akron Biotech
7.4.13.1. Overview
7.4.13.2. Product Benchmarking
7.4.13.3. Strategic Initiatives
7.4.14. AllCells
7.4.14.1. Overview
7.4.14.2. Product Benchmarking
7.4.14.3. Strategic Initiatives
7.4.15. CGT Global
7.4.15.1. Overview
7.4.15.2. Product Benchmarking
7.4.15.3. Strategic Initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America cell therapy human raw materials market, by region, 2018-2030 (USD Million)
Table 3 North America cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 4 North America cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 5 U.S. cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 6 U.S. cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 7 Canada cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 8 Canada cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 9 Europe cell therapy human raw materials market, by region, 2018-2030 (USD Million)
Table 10 Europe cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 11 Europe cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 12 Germany cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 13 Germany cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 14 UK cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 15 UK cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 16 France cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 17 France cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 18 Italy cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 19 Italy cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 20 Spain cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 21 Spain cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 22 Denmark cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 23 Denmark cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 24 Sweden cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 25 Sweden cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 26 Norway cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 27 Norway cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 28 Asia-Pacific cell therapy human raw materials market, by region, 2018-2030 (USD Million)
Table 29 Asia-Pacific cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 30 Asia-Pacific cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 31 China cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 32 China cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 33 Japan cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 34 Japan cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 35 India cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 36 India cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 37 South Korea cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 38 South Korea cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 39 Australia cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 40 Australia cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 41 Thailand cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 42 Thailand cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 43 Latin America cell therapy human raw materials market, by region, 2018-2030 (USD Million)
Table 44 Latin America cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 45 Latin America cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 46 Brazil cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 47 Brazil cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 48 Mexico cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 49 Mexico cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 50 Argentina cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 51 Argentina cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 52 MEA cell therapy human raw materials market, by region, 2018-2030 (USD Million)
Table 53 MEA cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 54 MEA cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 55 South Africa cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 56 South Africa cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 57 Saudi Arabia cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 58 Saudi Arabia cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 59 UAE cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 60 UAE cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
Table 61 Kuwait cell therapy human raw materials market, by product, 2018-2030 (USD Million)
Table 62 Kuwait cell therapy human raw materials market, by end-use, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Cell therapy human raw materials market: market outlook
Fig. 9 Cell therapy human raw materials competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Cell therapy human raw materials market driver impact
Fig. 15 Cell therapy human raw materials market restraint impact
Fig. 16 Cell therapy human raw materials market strategic initiatives analysis
Fig. 17 Cell therapy human raw materials market: product movement analysis
Fig. 18 Cell therapy human raw materials market: product outlook and key takeaways
Fig. 19 Product market estimates and forecast, 2018-2030 (USD Million)
Fig. 20 Cell culture media market estimates and forecast, 2018-2030 (USD Million)
Fig. 21 Cell culture sera market estimates and forecast, 2018-2030 (USD Million)
Fig. 22 Cell culture supplements market estimates and forecast, 2018-2030 (USD Million)
Fig. 23 Proteins market estimates and forecast, 2018-2030 (USD Million)
Fig. 24 Growth factors market estimates and forecast, 2018-2030 (USD Million)
Fig. 25 Nucleotides market estimates and forecast, 2018-2030 (USD Million)
Fig. 26 Other supplements market estimates and forecast, 2018-2030 (USD Million)
Fig. 27 Reagents & buffers market estimates and forecast, 2018-2030 (USD Million)
Fig. 28 Other raw materials market estimates and forecast, 2018-2030 (USD Million)
Fig. 29 Cell therapy human raw materials market: end-use movement analysis
Fig. 30 Cell therapy human raw materials market: end-use outlook and key takeaways
Fig. 31 Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2018-2030 (USD Million)
Fig. 32 CROs & CMOs market estimates and forecasts, 2018-2030 (USD Million)
Fig. 33 Academic & research facilities market estimates and forecasts,2018-2030 (USD Million)
Fig. 34 North America cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 35 U.S. cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 36 Canada cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 37 Europe cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 38 UK cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 39 Germany cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 40 France cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 41 Italy cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 42 Spain cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 43 Denmark cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 44 Sweden cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 45 Norway cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 46 Asia-Pacific cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 47 China cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 48 Japan cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 49 India cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 50 Thailand cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 51 South Korea cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 52 Australia cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 53 Latin America cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 54 Brazil cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 55 Mexico cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 56 Argentina cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 57 Middle East and Africa cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 58 South Africa cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 59 Saudi Arabia cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 60 UAE cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 61 Kuwait cell therapy human raw materials market estimates and forecasts, 2018-2030 (USD Million)
Fig. 62 Market share of key market players- Cell therapy human raw materials market

Companies Mentioned

  • Thermo Fisher Scientific, Inc
  • Merck KGaA
  • Actylis
  • ACROBiosystems
  • STEMCELL Technologies
  • Grifols, S.A.
  • Charles River Laboratories
  • RoosterBio, Inc.
  • PromoCell GmbH
  • Danaher
  • BioIVT
  • GeminiBio
  • Akron Biotech
  • AllCells
  • CGT Global

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedJanuary 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 2.82 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.44 Billion
Compound Annual Growth Rate22.3%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Cell Therapy Market Size, Share & Trends Analysis Report by Therapy Type (Autologous (Stem Cell Therapies, Non-stem Cell Therapies), Allogeneic), Therapeutic Area, Region, and Segment Forecasts, 2024-2030 - Product Image

Cell Therapy Market Size, Share & Trends Analysis Report by Therapy Type (Autologous (Stem Cell Therapies, Non-stem Cell Therapies), Allogeneic), Therapeutic Area, Region, and Segment Forecasts, 2024-2030

  • Report
  • 110 Pages
  • Global
From
Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase, Indication, Region, and Segment Forecasts, 2024-2030 - Product Image

Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase, Indication, Region, and Segment Forecasts, 2024-2030

  • Report
  • 120 Pages
  • Global
From
Cell Therapy Technologies Market by Product, Process, Cell Type, End-User - Global Forecast 2025-2030 - Product Image

Cell Therapy Technologies Market by Product, Process, Cell Type, End-User - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Cell Therapy Human Raw Materials Global Market Report 2024 - Product Image

Cell Therapy Human Raw Materials Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Cell Therapy Raw Materials Market Analysis & Forecast to 2024-2034: Market By Product; By End-user; and By Region - Product Image

Cell Therapy Raw Materials Market Analysis & Forecast to 2024-2034: Market By Product; By End-user; and By Region

  • Report
  • 200 Pages
  • Global
From

About the Cell Therapy Raw Materials Market

Cell therapy raw materials are biotechnological products used in the production of cell therapies. These materials are used to create cell therapies, which are treatments that involve the use of living cells to treat or prevent diseases. Cell therapy raw materials include cell culture media, reagents, and other components used in the production of cell therapies. These materials are essential for the production of cell therapies, as they provide the necessary nutrients and environment for the cells to grow and develop. Cell therapy raw materials are used in a variety of industries, including biopharmaceuticals, regenerative medicine, and tissue engineering. The cell therapy raw materials market is expected to grow significantly in the coming years due to the increasing demand for cell therapies. Some companies in the cell therapy raw materials market include Thermo Fisher Scientific, Merck KGaA, Lonza Group, Corning Incorporated, and Sigma-Aldrich. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.